title: A new strategy to inhibit the excision reaction catalysed by HIV-1 reverse transcriptase: compounds that compete with the template-primer.
abstract: Inhibitors of the excision reaction catalysed by HIV-1 RT (reverse transcriptase) represent a promising approach in the fight against HIV, because these molecules would interfere with the main mechanism of resistance of this enzyme towards chain-terminating nucleotides. Only a limited number of compounds have been demonstrated to inhibit this reaction to date, including NNRTIs (non-nucleoside RT inhibitors) and certain pyrophosphate analogues. We have found previously that 2GP (2-O-galloylpunicalin), an antiviral compound extracted from the leaves of Terminalia triflora, was able to inhibit both the RT and the RNase H activities of HIV-1 RT without affecting cell proliferation or viability. In the present study, we show that 2GP also inhibited the ATP- and PP(i)-dependent phosphorolysis catalysed by wild-type and AZT (3'-azido-3'-deoxythymidine)-resistant enzymes at sub-micromolar concentrations. Kinetic and direct-binding analysis showed that 2GP was a non-competitive inhibitor against the nucleotide substrate, whereas it competed with the binding of RT to the template-primer (K(d)=85 nM). As expected from its mechanism of action, 2GP was active against mutations conferring resistance to NNRTIs and AZT. The combination of AZT with 2GP was highly synergistic when tested in the presence of pyrophosphate, indicating that the inhibition of RT-catalysed phosphorolysis was responsible for the synergy found. Although other RT inhibitors that compete with the template-primer have been described, this is the first demonstration that these compounds can be used to block the excision of chain terminating nucleotides, providing a rationale for their combination with nucleoside analogues.
authors.affiliation: Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Navarra, 31008 Pamplona, Spain.
authors.forename: Carlos
authors.initials: C
authors.lastname: Cruchaga
authors.forename: Elena
authors.initials: E
authors.lastname: Anso
authors.forename: María
authors.initials: M
authors.lastname: Font
authors.forename: Virginia S
authors.initials: VS
authors.lastname: Martino
authors.forename: Ana
authors.initials: A
authors.lastname: Rouzaut
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Martinez-Irujo
mesh_terms: D017931:DNA Primers / Q000378:metabolism*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D015497:HIV-1 / Q000378:metabolism*; D006801:Humans; D047348:Hydrolyzable Tannins / Q000737:chemistry* / Q000378:metabolism* / Q000627:therapeutic use; D019384:Nucleic Acid Synthesis Inhibitors; D010936:Plant Extracts / Q000737:chemistry / Q000378:metabolism; D018894:Reverse Transcriptase Inhibitors / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D013698:Templates, Genetic; D029766:Terminalia / Q000737:chemistry; D015215:Zidovudine / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D017931:DNA Primers; D047348:Hydrolyzable Tannins; D019384:Nucleic Acid Synthesis Inhibitors; D010936:Plant Extracts; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; C115643:punicalin; D054303:HIV Reverse Transcriptase